| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.075 | 0.01 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.077 | 0.01 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.02 |